Disclosed herein is a method of treating Drug Resistant Epilepsy with ketamine.
Disclosed are pharmaceutical compositions of ketamine and methods of their use in treatment, such as in ketamine-assisted psychotherapy (KAP), including both single KAP sessions and KAP treatment regimes, to treat patients with behavioral addictions, such as gambling disorder, gaming disorder, compulsive sexual behavior disorder, and binge eating disorder, among others.
In general, systems for administering a dmg are provided. In an exemplary embodiment, a dmg administration system includes a dmg administration device configured to communicate with a computer system and at least one sensor configured to obtain sensor data and communicate the sensor data to the drug administration device. The dmg administration device is configured to utilize a first drug dosing scheme when a drug is delivered to a patient, determine a second drug dosing scheme for delivering a drug to the patient dependent on dosing data from the computer system and sensor data collected by the sensor during and/or after the delivery of the first drug according to the first drug dosing scheme, and utilize the second drug dosing scheme when the drug is delivered to the patient.
Various aspects and embodiments disclosed herein relate generally to treating an alcohol use disorder or neuroadaptations. Embodiments include compositions and methods for modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with alcohol use disorders, or a related clinical condition thereof. Other embodiments include methods and compositions for reducing the effects of adolescent alcohol drinking.
Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) identifying a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) selecting a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the sleep disorder is selected from the group consisting of difficulty with falling asleep; restlessness of sleep; difficulty getting comfortable; difficulty staying asleep; degree of deep sleep; degree of being rested when waking up for the day; difficulty with beginning the day; and degree of having enough sleep during the previous night. In some embodiments, the sleep disorder is associated with pain selected from the group consisting of fibromyalgia, neuropathic pain, osteoarthritis, and visceral pain. In some more particular embodiments, the visceral pain is selected from the group consisting of IBS associated pain and bladder pain.
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Embodiments of the disclosure include methods of increasing the efficacy of a fibroblast cell therapy for any medical condition, including degenerative disc disease, by providing at least one anti-inflammatory composition, exosomes and/or apoptotic bodies, stem cells, or a combination thereof; and administering the fibroblast cell therapy. The anti-inflammatory composition may comprise a composition that inhibits and/or reduces TNF-alpha, such as melatonin.
Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure.
The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders.
The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.